ICD-10 E78.00 is officially defined as "Pure hypercholesterolemia, unspecified." code E78.00 is referenced in 10 tracked payer policy changes from Independence Blue Cross and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E78.00 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross Medicare Advantage expanded coverage for inclisiran (Leqvio®) effective 2026-10-12. New covered indications include primary hypercholesterolemia in adults 18+, heterozygous familial hypercholesterolemia (HeFH) in adults 18+ and pediatric patients 12-<18 years, and homozygous familial hypercholesterolemia (HoFH) in pediatric patients 12-<18 years. ICD-10 code E78.010 (HoFH) was added to the policy.
Independence Blue Cross expanded coverage for inclisiran (Leqvio®) effective 2026-10-12 to include three new indications: primary hypercholesterolemia in adults 18+, heterozygous familial hypercholesterolemia (HeFH) in adults 18+ and pediatric patients 12-17, and homozygous familial hypercholesterolemia (HoFH) in pediatric patients 12-17. The policy adds ICD-10 code E78.010 (HoFH) and establishes specific LDL-C thresholds and statin therapy requirements for each indication.
Independence Administrators updated CAC testing policy to clarify that coronary artery calcium testing is medically necessary if it has not been performed within the preceding 5 years in eligible low-risk individuals. The policy effective 09/19/2026 specifies strict clinical criteria for coverage, including age 40-75, LDL 70-190 mg/dL, 10-year ASCVD risk 5-20%, and absence of multiple exclusionary conditions. All other uses remain experimental/investigational and non-covered.
Independence Blue Cross reissued policy 08.01.91a for Inclisiran (Leqvio®) with one diagnostic code change: replaced E78.01 (Familial hypercholesterolemia) with E78.011 (Heterozygous familial hypercholesterolemia [HeFH]) effective 10/01/2025. Medical necessity criteria and coverage remain unchanged. Billing teams must update coding systems to reflect the new ICD-10 code for claims.
Independence Administrators updated policy 09.00.58a effective 10/01/2025 to replace the generic ICD-10 code E78.01 (Familial hypercholesterolemia) with three more specific codes: E78.010 (Homozygous), E78.011 (Heterozygous), and E78.019 (Unspecified). Billing teams must update their systems to use the new granular diagnosis codes when submitting CAC testing claims for familial hypercholesterolemia cases.
Aetna's Clinical Policy Bulletin 0381 treats apolipoprotein B, one-time lipoprotein(a) and high-sensitivity CRP as medically necessary only when the stated criteria are met, and lists many other cardiovascular risk tests as experimental, investigational or unproven. Apolipoprotein B is medically necessary for adults aged 19 and older on stable lipid-lowering therapy who have met an LDL-C or non-HDL-C goal and have established ASCVD, cardiovascular-kidney-metabolic syndrome, type 2 diabetes, or elevated triglycerides, while repeated or serial apo B measurements without a documented change in therapy or clinical status are not covered. A single lipoprotein(a) test is medically necessary for all adults aged 19 and older and repeat Lp(a) testing is considered not medically necessary, and hsCRP is covered for adults aged 30 to 79 with no known ASCVD, a borderline 10-year PREVENT-ASCVD risk estimate of 3% to less than 5%, no current statin therapy, and uncertain LDL-lowering decisions after standard risk assessment and shared decision making.
Aetna covers inclisiran (Leqvio) for commercial medical plans, and precertification is required for members in applicable plan designs. Coverage depends on the prescriber being a cardiologist, endocrinologist, lipid specialist, or a prescriber specialized in the treatment of hypercholesterolemia, plus the member's ASCVD history, current LDL-C level, and statin therapy or statin intolerance. The recommended dose is 284 mg by subcutaneous injection initially, again at 3 months, and then every 6 months.
Aetna considers intensive cardiac rehabilitation programs (the Benson-Henry Institute Cardiac Wellness Program, the Ornish cardiac treatment program and the Pritikin Program) medically necessary as an alternative to traditional Phase II cardiac rehabilitation for members who meet the cardiac rehabilitation criteria, limited to 72 one-hour sessions, up to 6 per day, over a period of up to 18 weeks. Virtual delivery by real-time audio and video (excluding audio-only) is considered medically necessary when the telehealth program and member criteria are met, but hospital outpatient departments are not eligible for virtual telehealth services. Intensive cardiac rehabilitation is considered experimental, investigational or unproven for diabetes, hyperlipidemia, prostate cancer, metabolic syndrome and all other indications where effectiveness has not been established.
Aetna considers plasmapheresis, plasma exchange and therapeutic apheresis medically necessary for a list of indications. These include acute humoral rejection of renal transplants, acute severe neurological deficits from multiple sclerosis that respond poorly to high-dose glucocorticoids, severe (grades 3 to 5) Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) with severe or life-threatening symptoms, thrombotic thrombocytopenic purpura, and sickle cell disease. Plasmapheresis, plasma exchange or therapeutic apheresis for all other indications, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, sepsis or septic shock, and ulcerative colitis, is considered experimental, investigational, or unproven.
Independence Blue Cross reissued Policy 08.01.91a with no substantive coverage changes to Inclisiran (Leqvio). The policy replaced ICD-10 diagnosis code E78.01 (Familial hypercholesterolemia) with E78.011 (Heterozygous familial hypercholesterolemia [HeFH]) effective 10/01/2025. Medical necessity criteria, billing codes, and coverage determinations remain unchanged.
Watch E78.00
Get one email when a payer policy names E78.00, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.